Clinical Trials Browser

Terminated × Neoplasms × pembrolizumab × Clear all

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04268277 2026-02-27

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

Phase 2 Terminated

22 enrolled 20 charts

Lymphoid

Neoplasms, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT04157517 2026-01-29

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

45 enrolled 44 charts

Dermatologic

Melanoma, Neoplasms

NCT04964960 2025-10-31

Pembro+Chemo in Brain Mets

Phase 2 Terminated

3 enrolled 7 charts

CNSThoracic

Brain Neoplasms, Lung Neoplasms, Neoplasms

NCT04717375 2025-08-07

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Phase 1/2 Terminated

125 enrolled

Tumor-Agnostic

Neoplasms

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

Phase 1/2 Terminated

19 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04830124 2025-06-10

ARTISTRY-6

Phase 2 Terminated

173 enrolled

Dermatologic

Melanoma, Neoplasms

NCT03948763 2025-01-28

V941-001

Phase 1 Terminated

70 enrolled 18 charts

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02972034 2024-11-21

MK-8353-013

Phase 1 Terminated

111 enrolled 30 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase 1/2 Terminated

12 enrolled 8 charts

Head & Neck

Nasopharyngeal Carcinoma, Carcinoma, Head and Neck Neoplasms, Stomatognathic Diseases, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Nose Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Pharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT03799003 2024-11-01

A Study of ASP1951 in Subjects With Advanced Solid Tumors

Phase 1 Terminated

119 enrolled

DermatologicGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

NCT04128696 2024-07-10

INDUCE-3

Phase 3 Terminated

315 enrolled 31 charts

Head & Neck

Head and Neck Neoplasms, Neoplasms

NCT03416335 2024-05-30

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Phase 1/2 Terminated

36 enrolled 17 charts

Tumor-Agnostic

Neoplasms

NCT03709706 2024-02-23

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Phase 1/2 Terminated

34 enrolled 16 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05357898 2024-02-23

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

20 enrolled

Head & Neck

Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Recurrence

NCT04348916 2023-06-08

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Phase 1 Terminated

66 enrolled

BreastDermatologicGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03637803 2023-06-01

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

Phase 1/2 Terminated

63 enrolled

DermatologicGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

3 enrolled

Tumor-Agnostic

Neoplasms

NCT02376699 2023-05-01

Safety Study of SEA-CD40 in Cancer Patients

Phase 1 Terminated

159 enrolled

DermatologicHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Squamous Cell

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT04274907 2021-02-11

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Phase 1 Terminated

2 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03099161 2019-06-05

MK-3814A-062

Phase 1 Terminated

10 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

Clinical Trials

AcceleRET-Lung

Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY

A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Pembro+Chemo in Brain Mets

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

ARTISTRY-6

V941-001

MK-8353-013

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

A Study of ASP1951 in Subjects With Advanced Solid Tumors

INDUCE-3

A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Study of SQZ-eAPC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

TAILOR

Safety Study of SEA-CD40 in Cancer Patients

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

MK-3814A-062